Table 1

Clinical characteristics of patients with sera included in the cohort
Crescentic-positive AAV Crescentic-negative AAV Without renal biopsy
Total 15 25 45
Male/female 7/8 9/16 19/26
Age (years) 61 (8 to 78) 44 (7 to 76) 55 (20 to 78)
MPO-positive 14 22 40
Protease 3-positive 2 4 5
Complement 3 (g/l) 0.68 (0.44 to 1.18) 0.95 (0.06 to 1.83) 0.80 (0.36 to 1.99)
Serum creatinine (μmol/l) 736.5 (147.6 to 1,316) ##,* 165.0 (35.2 to 812.4) 381.1 (39.3 to 881)
24-hour proteinuria (g/24 hours) 0.47 (0.17 to 3.58) 0.83 (0.3 to 6.4) 1.80 (0.01 to 7.8)

Data presented as number or median (range). AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; MPO, myeloperoxidase. ##Difference between the crescentic-positive AAV patients and crescentic-negative AAV patients (P < 0.01). *Difference between the crescentic-positive AAV patients and AAV patients without a renal biopsy (P < 0.05).Note: Each group had one patient shown double positive MPO- and PR3- ANCA in crescentic-positive AAV and crescentic-negative AAV, respectively.

Zhang et al.

Zhang et al. Arthritis Research & Therapy 2013 15:R161   doi:10.1186/ar4344

Open Data